Parkinson's disease research has expanded from symptomatic management (dopaminergic drugs, DBS) toward neuroprotective and disease-modifying strategies targeting alpha-synuclein aggregation — the protein implicated in Lewy body pathology. Prodromal biomarker studies now aim to identify patients years before motor symptoms appear, when intervention may be most effective.
Trials test alpha-synuclein antibodies (prasinezumab, cinpanemab), GBA1 gene therapy, adaptive deep brain stimulation (aDBS), GLP-1 agonists (liraglutide, semaglutide), and nilotinib for neuroprotection. Skin biopsy and cerebrospinal fluid alpha-synuclein assays are emerging as enrollment biomarkers.
Disease-modifying trials often restrict enrollment to early-stage patients (Hoehn & Yahr 1–2.5) within a few years of diagnosis to capture sufficient disease duration for benefit detection.
Frequently Asked Questions — parkinsons disease Clinical Trials
How many clinical trials are currently recruiting for parkinsons disease?
ClinicalMetric currently tracks 1 actively recruiting clinical trials for parkinsons disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 1. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for parkinsons disease?
parkinsons disease research spans Phase 1 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a parkinsons disease clinical trial?
Eligibility criteria for parkinsons disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
Craig van Horne, MD, PhD 1 trial
Recruiting Clinical Trials
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional.
Full Disclaimer ·
Last Reviewed: April 2026 ·
Data Methodology